Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dabrafenib was well tolerated and led to durable responses in patients with BRAF-mutant differentiated thyroid carcinoma, with a median progression-free survival of 11.3 months.

This review highlights that frontal fibrosing alopecia’s increasing incidence may involve immune, genetic, hormonal, and environmental factors, yet its pathogenesis remains complex and not fully understood.

The Fas/FasL pathway may play a role in alopecia areata.

In this study, researchers identified genetic factors associated with frontal fibrosing alopecia, noting a protective effect of a specific CYP1B1 gene variant, which may offer insights into the disease's pathogenesis and future risk mitigation strategies.

The authors concluded that Hispanic/Latino ethnicity, facial papules, and premenopausal status in patients with frontal fibrosing alopecia may indicate a susceptibility to more severe disease, potentially necessitating early treatment.

This study found that serum FABP4 levels were significantly higher in alopecia areata patients compared to healthy controls and may correlate with disease severity.

This study found that A-FABP serum levels were significantly higher in male patients with androgenetic alopecia compared to controls, and the authors concluded that A-FABP could serve as a biomarker for early detection of this condition.

This study found that DEFB1 polymorphisms, specifically the rs1800972 CG and GG genotypes, may predict susceptibility to and severity of alopecia areata.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study found that certain circulating miRNAs in skin and plasma may serve as potential biomarkers for distinguishing frontal fibrosing alopecia from control cases, highlighting the need for further validation in larger cohorts.

This study identified mutations in the FGF5 gene as a cause of extreme eyelash growth in Pakistani families, highlighting a potential target for regulating eyelash growth.

Female pattern hair loss causes significant hair thinning and affects self-confidence.

This study evaluated treatments for frontal fibrosing alopecia and found hydroxychloroquine and 5a-reductase inhibitors to be most effective, with 70-72% of patients experiencing stabilization or improvement, but limitations in treatment consistency and assessment methods remain.

In this study, finasteride altered the expression of nine proteins in the rat nucleus accumbens, suggesting new therapeutic targets and mechanisms for its effects on neuropsychiatric conditions.

This study found that facial papules and rosacea in patients with frontal fibrosing alopecia were linked to a greater need for oral treatment, with most cases involving postmenopausal women.

This study found that older men with vertex balding had lower levels of IGFBP-3 and higher levels of IGF-1 in their plasma.

This review concludes that oral dutasteride has the highest evidence level for stabilizing frontal fibrosing alopecia and should be used as a first-line treatment until more randomized controlled trials are conducted.

This study found that FGF signaling is necessary for the initiation of feather placode development in chicken embryos, with FGF10 being implicated as an early dermal signal in the process.

This consensus statement discusses guidelines for screening, diagnosing, and treating the Female Athlete Triad, and introduces a risk stratification system to assist healthcare providers with sports participation decisions.

This review discusses changes and advancements in facial feminization surgery, detailing various aspects of the field but reporting no new clinical results; the authors highlight ongoing innovations and challenges.

In this research letter from the British Journal of Dermatology, the authors explore the use of topical tofacitinib to treat alopecia areata affecting facial hair, but specific results are not reported in the abstract.

This study suggests that frontal fibrosing alopecia is a highly inflammatory disease involving TH1 and JAK-STAT pathways, without reduced hair keratins, highlighting JAK-STAT signaling as a potential therapeutic target.

This study uncovered that bimatoprost, a prostaglandin analog, promotes hair growth by activating hair follicle progenitor cells through two pathways: the PTGFR-MAPK signaling axis and an unexpected IGF1R-PCAD-AKT signaling axis, suggesting new potential targets for treating hair disorders.

This study found that growth factor cocktail treatment including FGF9, combined with microneedling, significantly improved hair density in androgenetic alopecia patients compared to treatment with regular GFC or normal saline.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This consensus from 22 Spanish dermatologists recommends using a multimodal therapy starting with oral dutasteride, combined with topical and/or intralesional agents, and adding hydroxychloroquine if inflammation persists, to manage frontal fibrosing alopecia due to its irreversible hair loss and lack of specific approved treatments.

A woman with frontal fibrosing alopecia experienced unusual hair growth after using a specific topical lotion.

In this study, 2′‐Fucosyllactose (2′‐FL) administration significantly reduced hair loss and increased hair length and thickness in a testosterone-induced androgenic alopecia mouse model, suggesting potential as a therapeutic agent for AGA.

This literature review suggests that early and aggressive intervention may improve outcomes for avulsive ballistic facial injuries, although further comparative studies are needed.